-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

2576 HLA-Haploidentical Stem Cell Transplantation in Children with Inherited Bone Marrow Failure Syndromes: A Retrospective Analysis on Behalf of EBMT Severe Aplastic Anemia Working PartyClinically Relevant Abstract

Program: Oral and Poster Abstracts
Session: 509. Bone Marrow Failure and Cancer Predisposition Syndromes: Congenital: Poster II
Hematology Disease Topics & Pathways:
Bone Marrow Failure Syndromes, Inherited Marrow Failure Syndromes, pediatric, Diseases, clinical procedures, Technology and Procedures, Study Population, Human
Sunday, December 11, 2022, 6:00 PM-8:00 PM

Stefano Giardino, MD1*, Dirk-Jan Eikema2,3*, Brian Piepenbroek4*, Mattia Algeri, MD5*, Mouhab Ayas, MD6, Maura Faraci, MD7*, Abdelghani Tbakhi, MD8*, Marco Zecca, MD9*, Mohammed Essa10*, Bénédicte Neven, MD, PhD11*, Yves Bertrand, MD, PhD12*, Gaurav Kharya13*, Tatiana A Bykova, MD, PhD14*, Sarah Lawson, MBBS FRCPath15*, Mario Petrini16, Alexander Mohseny17*, Fanny Rialland, MD18*, Beki James19*, Anca Colita, MD20*, Mony Fahd, MD MSc21*, Simone Cesaro, MD22*, Ansgar Schulz, MD23*, Carlo Dufour, MD24, Antonio M Risitano, MD, PhD25,26 and Regis Peffault De Latour27*

1Unità di Trapianto di Cellule Staminali Emopoietiche - Dipartimento di Ematologia, Oncologia e Trapianto di Cellule Staminali Emopoietiche, IRCCS Istituto Giannina Gaslini, Genova, Italy
2LUMC, Dept. Medical Statistics & Bioinformatics, Leiden, Netherlands
3EBMT Statistical Unit, Leiden, Netherlands
4EBMT Leiden Study Unit, Leiden, Netherlands
5Department of Pediatric Hematology/Oncology, Cell and Gene Therapy, IRCCS Bambino Gesù Children's Hospital, Rome, Lazio, Italy
6Department of Pediatric Hematology/Oncology, King Faisal Specialist Hospital & Research Center, Riyadh, Middle, Saudi Arabia
7Unità di Trapianto di Cellule Staminali Emopoietiche - Department of Hematology, Oncology and Hematopoietic Stem Cell Transplantion, IRCSS, Istituto Giannina Gaslini, Genova, Italy
8King Hussein Cancer Centre, Amman, Jordan
9Pediatric Hematology/Oncology, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy
10Ministry of National Guard Health Affairs, King Abdulaziz Medical City, Riyadh, SAU
11Pediatric Immunology, Hematology and Rheumatology Unit, Hôpital Necker-Enfants Malades, AP-HP, Paris, France
12Unité de coordination interne et externe, Institut d`Hematologie et d`Oncologie Pediatrique, Lyon, France
13Indraprastha Apollo Hospitals, New Delhi, India
14RM Gorbacheva Research Institute, Pavlov University, St. Petersburg, Russian Federation
15Birmingham Children's Hospital, Birmingham, United Kingdom
16Azienda Ospedaliero Universitaria Pisana, Department of Clinical and Experimental Medicine, Hematology, Pisa, Italy
17Division of stem cell transplantation, Willem-Alexander Children’s Hospital, Leiden University Medical Center, Leiden, Netherlands
18Service Onco-Hématologie Pédiatrique, Hôpital Mère-Enfant, Nantes University Hospital, Nantes, France
19Leeds Children's Hospital, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom
20Fundeni Clinical Institute, University of Medicine Carol Davila, Bucharest, ROU
21Pediatric Hematology and Immunology Department, Robert-Debré Hospital, GH APHP Nord Université de Paris, Paris, France
22Pediatric Hematology-Oncology, Ospedale della Donna e del Bambino, Azienda Ospedaliera Universitaria Integrata, Verona, Italy
23Department of Pediatrics, University Medical Center, Ulm, Germany
24Department of Hemato-Oncology,, Hematology Unit, IRCCS G. Gaslini Children's Hospital, Genova, Italy
25Hematology and Hematopoietic Transplantation, AORN S. Giuseppe Moscati Avellino, Avellino, Italy
26Department of Clinical Medicine and Surgery, Federico II University of Naples, Naples, Italy
27Hematology and Transplantation Unit, Hôpital Saint Louis, AP-HP, Paris, France


HLA-haploidentical stem cell transplantation (HAPLO) has been widely used in the last years in children with an indication to receive an allogeneic hematopoietic stem cell transplantation (allo-HSCT) and lacking a matched donor. The introduction of new, more selective techniques of graft manipulation and in vivo T-cell depletion have improved the outcome of HAPLO in several diseases.

Allo-HSCT represents the only well-established cure for the hematological manifestations of inherited bone marrow failure syndromes (I-BMFs), featuring complex molecular pathophysiology resulting in ineffective hematopoiesis and increased risk of progression to myelodysplastic syndrome and acute leukemia. However, data on HAPLO in these diseases are limited.

This retrospective study aims to report the current outcomes of HAPLO in the EBMT network in patients with I-BMFs, comparing the different approaches introduced over the years.


The study was conducted on behalf of the Severe Aplastic Anemia Working Party of the EBMT. Data were collected from patients who underwent HAPLOs of I-BMFs and registered in the EBMT ProMISe database between 1990-2020 with a diagnosi. Clinical and biological information about the disease and details on transplant procedures and outcomes were collected through a specific case report form distributed to participating EBMT centers.


Data was collected from 162 patients (53.1% males) affected by I-BMFs undergoing HAPLO in 56 centers. The median age at HAPLO was 7.4 years (IQR 4.9-10.9). Table 1 summarizes the diagnoses and main HSCT details. Most HAPLOs were performed in 2015 (n=125, 77.2%).

Based on different T-cell depletion (TCD) approaches, 4 categories were identified: 1) TCRCD3+ or ab+/CD19+depletion performed in 71 transplants (43.8%); 2) T-repleted with post-transplant Cyclophosphamide (PTCy) in 55 (34.0%); 3) in vivo T-depletion approach in 24 (14.8%; 20 ATG, 4 anti-CD52); and 4) CD34+ positive selection in 12 (7.4%).

Neutrophil and platelet engraftment occurred on day + 14 (95% CI 13-15), and +18 (95% CI 16-21) respectively. Primary graft rejection was diagnosed in 14 children (10% [5-14%]), while 11 experienced secondary graft failure (8% [3-12%]).

The 100-day cumulative incidence of grade II-IV and III-IV acute GvHD (95% CI) was 29 % (22-36) and 13% (8-19), while the 24-month cumulative incidence of chronic GvHD was 11% (6-16%) and that for the extensive form was 4% (1-7%).

After a median follow-up of 43.4 months (IQR 32.9- 51), the 2-year overall survival (OS) and GvHD/Rejection-free Survival (GRFS) probability are 67% (60-74%) and 53% (45-61%) respectively (Figure 1). The main causes of death were infections (40.4%), GvHD (28.8 %), other HSCT-related events (28.85 %), and relapse of acute leukemia in 1 patient with malignant transformation (1.9 %).

When we analyzed the outcome by the modality of TCD, the TCR CD3+ab+/CD19+ depletion group showed the best OS (79%) and GRFS (71%) that were significantly higher (p 0.013 and p <0.001, respectively) than those observed in the other groups. (Figure 1). The TCR CD3+ab+/CD19+ depletion group also was associated with a lower incidence of acute (15%, vs 46 % PT-Cy, vs 9% CD34+ positive, vs 41% in-vivo TCD; p 0.001) and chronic GvHD (9%, vs 19% PT-Cy, vs 0% CD34+ positive selection vs 0 % in-vivo TCD; p < 0.041).

No differences in outcome were observed based on the underlying diagnosis.


This is the largest retrospective study on HAPLO in I-BMFs comparing the main TCD approaches and the long median follow-up of almost 4 years contributes to the reliability of the data reported.

The satisfactory outcome supports HAPLO HSCT as a safe and effective alternative for patients lacking a full-matched donor. The most widely adopted approaches are TCR CD3+ab+/CD19+ depletion and PT-Cy. PT-Cy is largely used because of its easy accessibility, but for the time being, the TCR CD3+ab+/CD19+ depletion platform offers the highest OS and GRFS and the lower incidence of both acute and chronic GvHD in I-BMFs.

Disclosures: Dufour: Pfizer: Consultancy; Sobi: Consultancy; Novartis: Consultancy; Biocryst: Consultancy; Gilead: Consultancy; Rockets: Consultancy. Risitano: Sobi: Honoraria, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Roche: Membership on an entity's Board of Directors or advisory committees; Pfizer: Honoraria, Speakers Bureau; Alnylam: Research Funding; Ra Pharma: Research Funding; Achillion: Membership on an entity's Board of Directors or advisory committees; Samsung: Membership on an entity's Board of Directors or advisory committees; Amyndas: Consultancy; Apellis: Honoraria, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Novartis: Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding, Speakers Bureau; Alexion: Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding, Speakers Bureau. Peffault De Latour: Samsung: Consultancy, Honoraria; Roche: Consultancy, Honoraria; Pfizer: Consultancy, Honoraria, Research Funding; MSD: Consultancy, Honoraria; Keocyte: Consultancy, Honoraria; Jazz: Consultancy, Honoraria, Research Funding; Gilead: Consultancy, Honoraria; Amgen: Consultancy, Honoraria, Research Funding; Alexion: Consultancy, Honoraria, Research Funding; Novartis: Consultancy, Honoraria, Research Funding; Sobi: Consultancy, Honoraria.

Previous Abstract | Next Abstract >>
*signifies non-member of ASH